Edition:
United Kingdom

Profile: Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

5.59USD
6:35pm BST
Change (% chg)

$-0.06 (-1.06%)
Prev Close
$5.65
Open
$5.68
Day's High
$5.68
Day's Low
$5.59
Volume
828
Avg. Vol
11,964
52-wk High
$9.80
52-wk Low
$3.35

Merrimack Pharmaceuticals, Inc., incorporated on July 6, 2010, is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. The Company’s development programs include four clinical trials and six candidates in preclinical development. The Company’s clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.

MM-121 (seribantumab)

MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. There are two active development programs for MM-121, each in a Phase II clinical trial. The Company is conducting the open-label, biomarker-selected, Phase II randomized SHERLOC clinical trial, evaluating MM-121 in combination with docetaxel in patients with heregulin positive non-small cell lung cancer, or NSCLC. The Company is also conducting the double-blinded, placebo-controlled, biomarker-selected, Phase II randomized SHERBOC clinical trial evaluating MM-121 in combination with fulvestrant in patients with heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, and metastatic breast cancer.

MM-141 (istiratumab)

MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. The Company is conducting a Phase II clinical trial in patients with untreated metastatic pancreatic cancer with high serum levels of free IGF-1 in combination with nab-paclitaxel and gemcitabine.

MM-310

MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The EphA2 receptor is expressed in most solid tumor types, such as prostate, ovarian, bladder, gastric, pancreatic and lung cancers. The Company initiated a Phase 1 clinical trial to evaluate safety and preliminary activity of MM-310 in patients with solid tumors.

Company Address

Merrimack Pharmaceuticals Inc

1 Kendall Sq Ste B7201
CAMBRIDGE   MA   02139-1670
P: +1617.4411000
F: +1617.4911386

Company Web Links